Scalper1 News
A wave of patent expirations over the past several years pushed drugmakers beyond the “blockbuster” drug era, helping foster a more innovative, rapidly evolving industry. Partly as a result, specialty, generic and biotech drugmakers hold almost 20% of the current IBD 50 list. Most of those stocks have already posted significant gains. Several, such as Jazz Pharmaceuticals (JAZZ) and Salix Pharmaceuticals (SLXP), are stabbing to new highs. Others Scalper1 News
Scalper1 News